{"id":13385,"date":"2021-09-16T18:28:07","date_gmt":"2021-09-16T12:58:07","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=13385"},"modified":"2021-10-22T15:46:54","modified_gmt":"2021-10-22T10:16:54","slug":"pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics","title":{"rendered":"FDA\u2019s New Drug Application to  ALS Drug; Approval to BeiGene\u2019s Brukinsa; Roche, Temedica Forges Digital Companionship, Shares of Sage Therapeutics Rises"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fb61dc978b7\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fb61dc978b7\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics\/#FDAs_Go-Ahead_to_Amylyx_New_Drug_Application_for_ALS_Drug\" >FDA\u2019s Go-Ahead to Amylyx New Drug Application for ALS Drug&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics\/#FDA_Approval_to_BeiGenes_Brukinsa_for_Advanced_Marginal_Zone_Lymphoma\" >FDA Approval to BeiGene\u2019s Brukinsa for Advanced Marginal Zone Lymphoma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics\/#Sage_Therapeutics_Witnesses_a_Rush_in_its_Share_Price\" >Sage Therapeutics Witnesses a Rush in its Share Price&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics\/#Roche_Temedica_to_Launch_%E2%80%98Digital_Companion_for_Multiple_Sclerosis\" >Roche, Temedica to Launch &#8216;Digital Companion&#8217; for Multiple Sclerosis<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-fda-s-go-ahead-to-amylyx-new-drug-application-for-als-drug\"><span class=\"ez-toc-section\" id=\"FDAs_Go-Ahead_to_Amylyx_New_Drug_Application_for_ALS_Drug\"><\/span><strong>FDA\u2019s Go-Ahead to Amylyx New Drug Application for ALS Drug&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Amylyx Pharmaceuticals has announced its plan to submit a New Drug Application (NDA) to the U.S. FDA for its drug, <strong>AMX0035 <\/strong>(sodium phenylbutyrate (PB) and <strong>Taurursodiol <\/strong>(TURSO)), for the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/amyotrophic-lateral-sclerosis-als-market\">treatment of Amyotrophic lateral sclerosis (ALS)<\/a><\/strong>.&nbsp;<\/p>\n\n\n\n<p>A few months ago, the company had decided to file for a marketing application to the different regulatory agencies seeking approval on the basis of the Phase II CENTAUR trial, which has shown that the drug showed survival benefit and met its primary endpoints. However, the USFDA had requested for Phase III trial to give its recommendation.&nbsp;<\/p>\n\n\n\n<p>In a recent announcement, the company made its intent to file for NDA clear that followed recent discussions with the FDA, including a pre-NDA meeting held on July 15, 2021.&nbsp;<\/p>\n\n\n\n<p><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/amyotrophic-lateral-sclerosis-als-epidemiology-forecast\">Amyotrophic lateral sclerosis<\/a><\/strong> continues to pose a significant healthcare burden, with curative therapies appearing not less than evasive prey for the scientific community. The present <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/amyotrophic-lateral-sclerosis-als-market\">ALS market<\/a><\/strong> comprises Radicava (Edaravone; Mitsubishi Tanabe Pharma), Rilutek (Riluzole; Covis Pharmaceuticals), Tiglutik (riluzole), Exservan and Nuedexta; however, none of the therapies are curative and are associated with concerns such as side effects or pricing.&nbsp;<\/p>\n\n\n\n<p>However, the company is optimistic about its drug as they claim it to be the drug that managed to improve both function and survival.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"FDA_Approval_to_BeiGenes_Brukinsa_for_Advanced_Marginal_Zone_Lymphoma\"><\/span><strong>FDA Approval to BeiGene\u2019s Brukinsa for Advanced Marginal Zone Lymphoma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>BeiGene is gushing with joy after the USFDA gave its nod to Brukinsa (zanubrutinib), a <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/brutons-tyrosine-kinase-btk-inhibitors-competitive-landscape-pipeline-and-market-analysis\">Bruton\u2019s tyrosine kinase (BTK) inhibitor<\/a><\/strong>, for treatment for adult patients with relapsed or refractory (R\/R) <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/marginal-zone-lymphoma-market\">marginal zone lymphoma (MZL)<\/a><\/strong>.<\/p>\n\n\n\n<p>The approval is based on the findings from two clinical studies-phase 2 MAGNOLIA clinical trial and another phase 1\/2 trial. The drug managed to shrink the disease with an impressive overall response rate.&nbsp;<\/p>\n\n\n\n<p>Brukinsa ( Zanubrutinib) is a small-molecule inhibitor of <strong>Bruton tyrosine kinase (BTK)<\/strong> and is already approved for the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/mantle-cell-lymphoma-market\">treatment of mantle cell lymphoma<\/a><\/strong> patients who received at least one prior therapy. Recently the drug received approval for adults with Waldenstr\u00f6m macroglobulinemia in the US and now managed to score another, expanding its profile.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Sage_Therapeutics_Witnesses_a_Rush_in_its_Share_Price\"><\/span><strong>Sage Therapeutics Witnesses a Rush in its Share Price&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Sage Therapeutics shares leaped after the company announced that the USFDA had granted&nbsp; Fast Track Designation to its drug SAGE-718 for a debilitating disorder of the brain, <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-market\">Huntington\u2019s disease (HD)<\/a><\/strong>. The designation will help the company to take its orphan drug to patients in the market comparatively earlier.&nbsp;<\/p>\n\n\n\n<p><strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/huntingtons-disease-epidemiology-forecast\">Huntington\u2019s disease<\/a><\/strong> is a rare, inherited neurodegenerative disorder with a prevalence of 80, 170 in 2020 in the 7MM, which is further expected to grow in the coming years. The rare disorders market faces a dearth of curative therapies despite widespread cumulative prevalence owing to several challenges such as difficulty in conducting trials, lack of understanding and knowledge of pathophysiology and so on.&nbsp;<\/p>\n\n\n\n<p>However, measures by the regulatory authorities such as providing market exclusivities, waivers in fees and taxes and so on have helped facilitate the development of rare drugs.&nbsp;<\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Roche_Temedica_to_Launch_%E2%80%98Digital_Companion_for_Multiple_Sclerosis\"><\/span><strong>Roche, Temedica to Launch &#8216;Digital Companion&#8217; for Multiple Sclerosis<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Germany\u2019s Temedica and Swiss pharma giant Roche have come together in pursuit of providing digital support to <strong>Multiple sclerosis patients<\/strong>. The duo has decided to design a new mobile app to deepen understanding of the disease based on real-world data gained from <a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-epidemiology-forecast\"><strong>Multiple Sclerosis<\/strong> <strong>patients<\/strong><\/a>.<\/p>\n\n\n\n<p>The Brisa platform leverages Roche\u2019s medical expertise compounded with Temedica\u2019s experience in developing digital health tools.&nbsp;<\/p>\n\n\n\n<p>The mobile app, dubbed <strong>Brisa<\/strong>, is expected to collect daily health data like activity, sleep, and dietary habits to help track the <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/multiple-sclerosis-epidemiology-forecast\">symptoms of Multiple Sclerosis<\/a><\/strong>, which will help the areas of improvement, suggest lifestyle changes to add to the efficiency of the existing therapies. The app also has a feature to provide individualized therapy support while simultaneously sharing the updates with the physicians.\u00a0<\/p>\n\n\n\n<p>As the emerging technologies continue to fascinate and transform healthcare, several pharma companies are now looking out to expand their expertise in the therapeutic areas by exploring AI and digital means. Looking at an increasing number of collaborations between pharma tycoons and digital healthcare service providers, it is quite transparent that the digital era in healthcare has finally started to gain the traction and importance it deserved.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>FDA\u2019s Go-Ahead to Amylyx New Drug Application for ALS Drug&nbsp; Amylyx Pharmaceuticals has announced its plan to submit a New Drug Application (NDA) to the U.S. FDA for its drug, AMX0035 (sodium phenylbutyrate (PB) and Taurursodiol (TURSO)), for the treatment of Amyotrophic lateral sclerosis (ALS).&nbsp; A few months ago, the company had decided to file [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":13388,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[74,18832,420,639],"industry":[17225],"therapeutic_areas":[17229,17238,17245,17228,17244],"class_list":["post-13385","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-amyotrophic-lateral-sclerosis","tag-marginal-zone-lymphoma","tag-news","tag-pharma-news","industry-pharmaceutical","therapeutic_areas-central-nervous-system","therapeutic_areas-genetic-disorders","therapeutic_areas-neurology","therapeutic_areas-oncology","therapeutic_areas-ophthalmology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BeiGene\u2019s Brukinsa; Roche-Temedica&#039;s Partnership; Amylyx&#039;s ALS Drug<\/title>\n<meta name=\"description\" content=\"FDA\u2019s Go-Ahead to Amylyx&#039;s AMX0035 and Taurursodiol; FDA Approval to BeiGene\u2019s Brukinsa; Roche-Temedica to Launch Digital Companion; Sage Th\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeiGene\u2019s Brukinsa; Roche-Temedica&#039;s Partnership; Amylyx&#039;s ALS Drug\" \/>\n<meta property=\"og:description\" content=\"FDA\u2019s Go-Ahead to Amylyx&#039;s AMX0035 and Taurursodiol; FDA Approval to BeiGene\u2019s Brukinsa; Roche-Temedica to Launch Digital Companion; Sage Th\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-16T12:58:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-22T10:16:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/09\/16182656\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeiGene\u2019s Brukinsa; Roche-Temedica's Partnership; Amylyx's ALS Drug","description":"FDA\u2019s Go-Ahead to Amylyx's AMX0035 and Taurursodiol; FDA Approval to BeiGene\u2019s Brukinsa; Roche-Temedica to Launch Digital Companion; Sage Th","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics","og_locale":"en_US","og_type":"article","og_title":"BeiGene\u2019s Brukinsa; Roche-Temedica's Partnership; Amylyx's ALS Drug","og_description":"FDA\u2019s Go-Ahead to Amylyx's AMX0035 and Taurursodiol; FDA Approval to BeiGene\u2019s Brukinsa; Roche-Temedica to Launch Digital Companion; Sage Th","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2021-09-16T12:58:07+00:00","article_modified_time":"2021-10-22T10:16:54+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/09\/16182656\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics","url":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics","name":"BeiGene\u2019s Brukinsa; Roche-Temedica's Partnership; Amylyx's ALS Drug","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/09\/16182656\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics.jpg","datePublished":"2021-09-16T12:58:07+00:00","dateModified":"2021-10-22T10:16:54+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"FDA\u2019s Go-Ahead to Amylyx's AMX0035 and Taurursodiol; FDA Approval to BeiGene\u2019s Brukinsa; Roche-Temedica to Launch Digital Companion; Sage Th","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/09\/16182656\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/09\/16182656\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics.jpg","width":772,"height":482,"caption":"pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2021\/09\/16182656\/pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">amyotrophic lateral sclerosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Marginal Zone Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">amyotrophic lateral sclerosis<\/span>","<span class=\"advgb-post-tax-term\">Marginal Zone Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Sep 16, 2021","modified":"Updated on Oct 22, 2021"},"absolute_dates_time":{"created":"Posted on Sep 16, 2021 6:28 pm","modified":"Updated on Oct 22, 2021 3:46 pm"},"featured_img_caption":"pharma-happenings-for-amylyx-beigene-roche-temedic-sage-therapeutics","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/13385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=13385"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/13385\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/13388"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=13385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=13385"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=13385"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=13385"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=13385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}